Starving cancer cells to enhance DNA damage and immunotherapy response
A new research perspective titled “Starving cancer cells to enhance DNA damage and immunotherapy response” has been published in Oncotarget.
Oncology & Cancer
Slowing inflammation may boost immunotherapy’s effectiveness against advanced lung cancer
Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Cent…
Team finds exportin 1 governs immunosuppressive functions of myeloid-derived suppressor cells in tumors
A team of Roswell Park Comprehensive Cancer Center experts led by Hemn Mohammadpour, DVM, Ph.D., has conducted research that offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy.
Study shows CAR NK cells with CD28 costimulation improve cell persistence and antitumor activity
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from Th…
A new ‘one-two punch’ method for improving checkpoint inhibitor therapy for cancers, including Hodgkin lymphoma
Checkpoint inhibitor therapies can be thought of as the molecular “brake release” for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells in the body. While there are m…
Study identifies mechanism behind glioblastoma’s immunotherapy resistance
The cells of a rare, deadly cancer are resistant to immunotherapy. Now researchers may have found the cause, paving the way for a new type of treatment.
Drug reprograms immune responses to target glioblastoma
Investigators from Northwestern University Feinberg School of Medicine and The University of Texas MD Anderson Cancer Center have discovered that using a novel drug to target the STING pathway in glioblastoma reprogrammed previously suppressed immune r…
FDA official: The risk of secondary cancer from CAR-T therapy is less than feared
The risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared last year, an FDA official said June 14 at cell and gene therapy conference in King of Prussia.
Nano-immunotherapy developed to improve lung cancer treatment
Researchers at Brigham and Women’s Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system’s ability to fight cancer.
Fasting primes the immune system’s natural killer cells to better fight cancer, new study in mice finds
Periods of fasting reprogram the immune system’s natural killer cells to better fight cancer, according to a new study in mice from researchers at Memorial Sloan Kettering Cancer Center (MSK).